Answer
The breast-cancer indication is limited to people with a harmful or suspected harmful inherited BRCA1 or BRCA2 mutation. Testing confirms whether the cancer meets this requirement and may prompt genetic counselling.
Sources for this answer
- Talzenna 0.1mg hard capsules — Current selected SmPCemc · Summary of Product Characteristics
- NHSNHS · NHS medicine guidance